A Phase 2/3 interventional study of Rilogrotug and Placebo in Cachexia; Cancer, Cachexia and Cachexia-Anorexia Syndrome, sponsored by AVEO Pharmaceuticals, Inc.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by AVEO Pharmaceuticals, Inc. (part of LG Chem) · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this trial is to learn whether participants who take rilogrotug gain weight, have a better appetite, and have a better quality of life than participants who do not take rilogrotug (placebo arm). Adult participants with cachexia who have also been diagnosed with metastatic colorectal or non-small cell lung cancer will be enrolled.
The primary hypothesis is that after 12 weeks, rilogrotug will cause an increase from baseline in body weight and appetite (as measured by the Functional Assessment of Anorexia/Cachexia Therapy 5-item Anorexia Symptom Scale [FAACT-5IASS] questionnaire) compared to placebo.
This multicenter, randomized, double-blind, placebo-controlled Phase 2/3 study is designed to compare the efficacy and safety of rilogrotug to a control arm of placebo for treatment of weight loss and anorexia in participants with cachexia who have also been diagnosed with metastatic colorectal cancer (mCRC) or metastatic non-small cell lung cancer (mNSCLC) and are receiving first line anticancer standard of care. The master protocol is designed with 4 sub-studies:
The Phase 2 (A) sub-study is designed to compare the efficacy and safety of two dose levels of rilogrotug (Arm 1 or Arm 2) to a control arm of placebo (Arm 3) in a 1:1:1 allocation. It is anticipated that the sub-study will enroll approximately 150 participants across 3 arms.
The Phase 3 (B) sub-study is designed to assess safety and efficacy of the selected optimal dose versus placebo in patients with cancer cachexia and mCRC in a 1:1 allocation. It is anticipated that the sub-study will enroll approximately 400 participants across 2 arms.
The Phase 3 (C) sub-study is designed to assess safety and efficacy of the selected optimal dose versus placebo in patients with cancer cachexia and mNSCLC in a 1:1 allocation. It is anticipated that the sub-study will enroll approximately 400 participants across 2 arms.
The OLE (D) sub-study is designed to allow participants who have completed one of the parent sub-studies (A), (B), (C) to continue receiving rilogrotug for up to an additional 12 months.
331 studies on the registry are indexed under Cachexia; 74 are open to participants now.
This study's planned enrollment of 950 is above the median of 74 across 226 interventional studies indexed under Cachexia.
Browse Cachexia studies →AVEO Pharmaceuticals, Inc. is the lead sponsor of 35 studies on the registry; 2 are open to participants now.
First submitted after AVEO Pharmaceuticals, Inc. became part of LG Chem.
Counted across the registry records on this site, refreshed daily.
The criteria were revised on the registry on Oct 28, 2026. See what changed
Phase 2 (A), Phase 3 (B) \& (C) Inclusion Criteria (IC):
Phase 2 (A), Phase 3 (B) \& (C) Exclusion Criteria (EC):
OLE (D) IC:
OLE (D) EC:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
intravenous (IV) administration
Biological: Rilogrotug
IV administration
Biological: Rilogrotug
IV administration
Biological: Placebo
Rilogrotug (AV-380) is a humanized immunoglobulin G1 kappa monoclonal antibody that binds to growth differentiation factor-15 (GDF-15).
Placebo for this study will be normal saline.
Phase 2 (A): To evaluate the effect of rilogrotug compared to placebo on weight gain
Percent change from baseline in body weight
Time frame: 12 weeks
Phase 2 (A): Change from baseline in Functional Assessment of Anorexia/Cachexia Therapy- 5-Item Anorexia Symptom Scale score
Scale has five items, each rated 0-4. Total score ranges from 0 (minimum) to 20 (maximum). Higher score is associated with a better outcome.
Time frame: 12 weeks
Phase 3 (B): To evaluate the effect of rilogrotug compared to placebo on weight gain
Percent change from baseline in body weight
Time frame: 12 weeks
Phase 3 (B): Change from baseline in Functional Assessment of Anorexia/Cachexia Therapy- 5-Item Anorexia Symptom Scale score
Scale has five items, each rated 0-4. Total score ranges from 0 (minimum) to 20 (maximum). Higher score is associated with a better outcome.
Time frame: 12 weeks
Phase 3 (C): To evaluate the effect of rilogrotug compared to placebo on weight gain
Percent change from baseline in body weight
Time frame: 12 weeks
Phase 3 (C): Change from baseline in Functional Assessment of Anorexia/Cachexia Therapy- 5-Item Anorexia Symptom Scale score
Scale has five items, each rated 0-4. Total score ranges from 0 (minimum) to 20 (maximum). Higher score is associated with a better outcome.
Time frame: 12 weeks
OLE (D): To evaluate the safety and tolerability of long-term rilogrotug administration
Adverse events and Laboratory abnormalities
Time frame: 52 weeks
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Mar 2030, 40 months later.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: start Feb 2027 → Nov 2026, primary completion Oct 2028 → Mar 2030 and completion Jan 2031 → Oct 2031.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rilogrotug